For many UK high-growth technology and life sciences enterprises the US is a highly attractive place to expand and raise later-stage funding than the United States.  The US offers the promise of massive commercial opportunities and plentiful venture and growth capital.  However, doing business and raising money in this highly-competitive environment with very different dynamics to the UK requires thoughtful advance planning and clinical execution. 

 In this facilitated Q&A session, we will discuss best practices for navigating the logistical aspects of launching and operating a UK business in the States, and setting, as well as meeting expectations for US later-stage funding.

The discussion will be led by Daniel Glazer, who leads the US Expansion group at Silicon Valley-headquartered Wilson Sonsini.  Dan divides his time between London and New York, assisting technology-driven UK companies with US expansion, fundraising and strategic partnership transactions.  Also joining will be New York-based Wilson Sonsini partner Megan Baier, who advises UK and US life sciences, healthcare and digital health companies on US IPOs, VC financings, and M&A transactions.

Here’s a sample of various frequently-asked questions:

  • When should I seriously consider establishing US operations?
  • When should I look to raise money from US VCs?
  • Do I need a US company to raise money from US VCs?
  • When do I need to create a US company?
  • Where is the best place to set up in the States?
  • How long does US set up take and how much does it cost?
  • How do I sell/pitch in the US as a British/non-US founder?
  • How is hiring different in the US, and what’s the optimal US team?
  • Does everyone really sue each other all the time in the US?
  • Are there government resources to assist with US expansion?


5 June 2018 from 8:30 am


Hauser Forum, 3 Charles Babbage Road, CB3 0GT